STOCK TITAN
  1. Home
  2. News
  3. MYGN

Myriad Genetics, Inc. - MYGN STOCK NEWS

Welcome to our dedicated news page for Myriad Genetics (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Myriad Genetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Myriad Genetics's position in the market.

News
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
Rhea-AI Summary
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor. Myriad Genetics, Inc. (NASDAQ:MYGN) reveals that 80% of people diagnosed with anxiety and depression report losing years or decades of time due to poor mental health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Rhea-AI Summary
Myriad Genetics, Inc. announced a study demonstrating exceptional positive predictive value for 22q11.2 microdeletion screening using their prenatal cell-free DNA screen, Prequel®. The study showed a 100% PPV for 22 patients who screened positive for 22q11.2 microdeletion. This breakthrough technology could significantly impact prenatal screening accuracy and patient management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
News
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) released results from a study showing reduced hospitalizations in patients with major depressive disorder after taking the GeneSight test. The study indicated a significant decrease in psychiatric-related hospitalizations and overall healthcare costs. Patients prescribed medications with no or moderate gene-drug interactions saw a decrease in hospitalizations. The GeneSight test potentially improves clinical outcomes and reduces healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
News
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Rhea-AI Summary
Myriad Genetics, Inc. secures a patent from the USPTO for a tumor-informed MRD assay, enhancing its precision medicine capabilities. The patent covers a method for preparing cell free DNA to detect circulating tumor DNA with high sensitivity and specificity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
News
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Rhea-AI Summary
Myriad Genetics, Inc. announced the grant of a patent by the U.S. Patent and Trademark Office for push-button blood collection devices for fetal sex determination. The patent covers SneakPeek Snap® products until 2040, ensuring accuracy in testing by reducing DNA contamination in maternal blood samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
News
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
Rhea-AI Summary
Myriad Genetics (MYGN) reported strong financial results for the full-year 2023, with a 35% growth in testing volume and $753 million in revenue, up 11% year-over-year. The company also raised $118 million in an equity offering and acquired assets from Intermountain Precision Genomics. They raised their 2024 revenue guidance to $820 - $840 million and introduced adjusted EPS guidance of $0.00 - $0.05.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
earnings
News
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Rhea-AI Summary
Myriad Genetics collaborates with NCCHE in Japan to study MRD testing's prognostic value across various cancer types using Precise MRD test. The SCRUM-MONSTAR-SCREEN-3 study aims to monitor ctDNA in patients with solid tumor and hematological cancers to develop personalized treatment strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
clinical trial
-
News
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Rhea-AI Summary
Myriad Genetics, Inc. announces participation in upcoming healthcare conferences and fourth quarter earnings conference call. Management will provide financial overview, business update, and guidance for 2024. Live webcast available for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
earnings
-
News
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
Rhea-AI Summary
Myriad Genetics appoints Dr. Dallas Reed as Principal Medical Advisor to women's health unit, focusing on genetic testing and precision medicine. Dr. Reed brings extensive clinical and academic experience in genetics and obstetrics/gynecology to enhance access and equity in genetic testing for women's health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
management
News
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) has completed the acquisition of select assets from Intermountain Health, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. The Precise Tumor Test analyzes a patient’s tumor DNA to discover and target important variants within tumors, while Precise Liquid will provide comprehensive genomic profiling results from a blood draw. This acquisition allows Myriad to expand its tumor profiling offerings and complement its oncology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
acquisition
Stock MYGN logo
Myriad Genetics, Inc.

Nasdaq:MYGN

MYGN Rankings

#2001 Ranked by Market Cap
#4003 Ranked by Stock Gains
N/A Ranked by Dividends

MYGN Stock Data

1.76B
74.68M
2.01%
103.03%
6.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Salt Lake City

About MYGN

myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.